On Wednesday, Telomir Pharmaceuticals, Inc. TELO announced that it had secured $3 million in equity financing through a direct investment by The Bayshore Trust, the company's largest shareholder.
The transaction involved the purchase of 1 million restricted shares of the company's common stock at $3.00 per share, representing an 18% premium to Telomir's closing share price of $2.54 on the execution date.
The transaction was structured as a straight restricted common stock transaction.
Also Read: Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
This transaction follows a prior $1 million equity investment at $7.00 per share made on December 9, 2024, through The Starwood Trust, an entity affiliated with the company's largest shareholder, and complements an existing $5 million non-dilutive line of credit from the same affiliated group, which remains undrawn.
Telomir Chair and CEO Erez Aminov said it had raised $4 million in equity and secured a $5 million credit line through affiliated entities.
Telomir said its priority was to submit its IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way.
Telomir is advancing two highly innovative drug candidates, Telomir-1, a first-in-class age-reversal molecule targeting the root causes of cellular decline, and Telomir-Ag2, a stabilized Silver(II) compound to address the growing threat of drug-resistant infections.
Telomir-1 is an oral small molecule that addresses five fundamental biological drivers of aging and chronic disease: mitochondrial dysfunction, oxidative stress, calcium imbalance, toxic metal accumulation (iron and copper), and telomere shortening.
In preclinical models, Telomir-1 has demonstrated reversal of the biological clock, improving both lifespan and health span, improvement of mitochondrial energy production in metabolically stressed cells, reduction of oxidative stress (ROS), a key contributor to age-related damage, correction of calcium signaling pathways associated with neurodegeneration and cell death, protection against metal-induced toxicity from iron and copper and Telomere lengthening and stabilization to support cellular regeneration.
Telomir-Ag2 is a novel Silver(II) complex stabilized using Telomir's proprietary chelation platform. Silver(II) has historically shown strong antimicrobial potential but has remained clinically impractical due to its instability -- until now.
Preclinical studies demonstrated that Telomir-Ag2 is active against Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus, and Methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA).
Price Action: TELO stock closed lower by 10.4% at $2.28 on Tuesday.
Read Next:
Intel Eyes Exit From Networking And Edge Business To Refocus On PC, Data Center Dominance: Report TELOTelomir Pharmaceuticals Inc$2.5410.9%Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock - anytime.
Reveal Full ScoreEdge RankingsMomentum6.96Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs